- Bend Bulletin main site
- Bend Bulletin archives
- Terms of Use
- Privacy Policy
- Contact the Bulletin
- Comments/Questions?
Published daily in Bend, Oregon, by Western Communications, Inc. Copyright 2007.
By Michelle Fay Cortez / The Bulletin
March 19, 2010
One of the most eagerly anticipated studies of a drug for Alzheimer’s disease may not yield results until 2012, two years later than had been forecast.
Johnson & Johnson took over development of the medicine, bapineuzumab, when it bought Elan Corp.’s Alzheimer’s program last year. Patients....
